Song et al. reported that increasing lymphangiogenesis in the meninges with VEGF-C treatment promotes the migration of CD8+ T cells into the dCLNs and tumor site to evoke a long-lasting T-cell immune response and subsequently improves survival in a GBM mouse model. This evidence concerns the gene VEGFC and glioblastoma.